Chemically Crosslinked Alginic Acid Hydrogel for Islet Transplantation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current pancreatic islet transplantation methods face challenges such as donor shortages, immune rejection reactions, complications from immune suppressants, and the risk of thrombus formation, with existing bioartificial pancreas technologies not providing effective long-term solutions.

Innovation Solution

A transplantation device using a chemically crosslinked alginic acid hydrogel encapsulates insulin-secreting cells or pancreatic islets, formed by chemical crosslinking of alginic acid derivatives with cyclic alkyne and azide groups, allowing for a Huisgen reaction to create a stable and semipermeable transplantation environment.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Speed

If microcapsule type bioartificial pancreas is used, then rapid nutrient permeation and cell response are achieved, but the microcapsules are difficult to collect when islet function declines

Engineering Contradiction:
Improvenutrient permeation speedVSAvoidease of collection
Core Design Contradiction:
SpeedVSEase of operation

Solution Approach 1:

The invention divides the encapsulation system into two distinct components: microcapsules containing individual islets for rapid nutrient permeation, and a macrocapsule structure that encompasses multiple microcapsules and enables easy collection. This segmentation allows each component to fulfill its specific function while resolving the contradiction between rapid permeation and ease of collection.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The invention employs a nested structure where microcapsules are placed inside a macrocapsule. The microcapsules maintain their small size for rapid nutrient diffusion, while the outer macrocapsule provides a larger containment structure that facilitates easy retrieval and collection of all encapsulated islets together when function declines.

Inventive Principle:
Principle #7Nested doll (Nesting)

2Reliability

If hemoperfusion type bioartificial pancreas is used, then immune isolation is achieved, but there is a severe risk of thrombus formation

Engineering Contradiction:
Improveimmune isolation effectivenessVSAvoidthrombus formation risk
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention extracts the blood perfusion component from the system, eliminating the hemoperfusion mechanism that causes thrombus formation. Instead, the invention uses direct implantation of encapsulated islets that rely on diffusion-based nutrient supply, thereby maintaining immune isolation benefits while removing the harmful thrombus formation risk associated with blood contact.

Inventive Principle:
Principle #2Taking out (Extraction)

3Ease of operation

If macrocapsule type bioartificial pancreas is used, then extraction is enabled when islet function declines, but no outstanding results have been reported for long-term survival and functional maintenance

Engineering Contradiction:
Improveease of extractionVSAvoidlong-term survival duration
Core Design Contradiction:
Ease of operationVSDuration of action of stationary object

Solution Approach 1:

The invention applies different material properties to different parts of the encapsulation system. The macrocapsule is designed with specific mechanical and chemical properties that enable easy extraction when needed, while the microcapsules and hydrogel matrix are engineered with properties that promote long-term islet survival and function. This local differentiation of material qualities allows simultaneous achievement of ease of extraction and long-term functional maintenance.

Inventive Principle:
Principle #3Local quality

4Productivity

If conventional pancreatic islet transplantation is used, then insulin secretion is restored, but immune rejection reactions occur necessitating long-term administration of immune suppressants

Engineering Contradiction:
Improveinsulin secretion functionVSAvoidimmune rejection reactions
Core Design Contradiction:
ProductivityVSObject-generated harmful factors

Solution Approach 1:

The invention introduces an intermediary encapsulation system consisting of microcapsules and macrocapsules with semipermeable membranes. This intermediary structure physically separates the transplanted islets from the recipient's immune system while allowing selective passage of nutrients, insulin, and waste products. The encapsulation barrier prevents immune cells from直接接触 the islets, thereby eliminating immune rejection reactions and the need for long-term immune suppressant administration while maintaining insulin secretion function.

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The device provides long-term biocompatibility, stability, and sustained blood glucose regulation with minimal adhesion or inflammation, enabling the transplantation device to maintain pancreatic islet function and be collected when necessary, addressing the limitations of existing technologies.

Implementation Method 1

chemical crosslinking of alginic acid derivatives with cyclic alkyne and azide groups, allowing for a Huisgen reaction to create a stable and semipermeable transplantation environment

Methodology Applied
Scientific EffectHuisgen reaction: Chemical Bonding

Implementation Method 2

encapsulated in a polymer gel, semipermeable membrane or the like capable of isolating the islets from the recipient's immune cells and the like while allowing permeation of nutrients, insulin and the like

Methodology Applied
Scientific EffectSemipermeable membrane filtration: Semipermeable Membrane

Data Source

PatentEP3991792B1Transplantation device using chemically crosslinked alginic acid
Publication Date: 2025.06.25 MOCHIDA PHARM CO LTD
  • EP3991792B1 patent drawingFigure 1(a)~1(b)
  • EP3991792B1 patent drawingFigure 2(a)~2(b)
  • EP3991792B1 patent drawingFigure 3(a)~3(b)

AI summary

Provided is a transplantation device comprising a hydrogel in which insulin-secreting cells or pancreatic islets are enclosed, wherein the hydrogel is prepared by gelatinizing an alginic acid derivative by a chemical crosslinkage. Thus, a novel transplantation device is provided.